0001453687-26-000082
SEC filingA challenging quarter marked by a sharp revenue decline and widening losses, driven by increased R&D spending on the Phase 3 AURORA trial and a non-cash charge from the CVR liability.
Revenue plummeted 92.9% year-over-year to just $78,000, driven entirely by a decrease in grant revenue from the National Institute of Neurological Disorders and Stroke (NINDS). The prior-year period included $1.1 million in grant reimbursements, which have now largely concluded. This highlights the company's reliance on non-dilutive funding sources and the lumpy nature of grant income. With no product revenue, the topline will remain minimal until a candidate reaches commercialization.
Operating loss widened 21.1% to $26.5 million, primarily due to increased expenses for Descartes-08 for myasthenia gravis (MG), particularly costs related to the ongoing Phase 3 AURORA trial. These costs include compensation for R&D employees, capital equipment, supplies for process development and manufacturing, and other related expenses. The increase was partially offset by decreased expenses reimbursable under the NINDS grant.
Net loss increased to $39.2 million from $17.7 million in the prior-year quarter, reflecting the higher operating loss and a non-cash loss from the fair value adjustment of the contingent value right (CVR) liability, which was primarily due to the passage of time. Diluted EPS was $(1.46) compared to $(0.68).
The company expects to continue incurring losses, with losses increasing as it advances development of product candidates, seeks regulatory approvals, and potentially commercializes any approved products. Primary uses of capital include compensation, third-party clinical research and development services, laboratory supplies, clinical costs, legal and regulatory expenses, milestone and royalty payments, and general overhead.